Vanda Pharmaceuticals (VNDA) News Today

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is drawing investor attention after a mix of analyst commentary and a bullish long-term outlook, even though near-term earnings remain pressured.

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $21 price target on Vanda, while raising several near- and medium-term EPS estimates, including Q1 2027, Q2 2027, Q3 2027, and Q4 2027, which suggests improving expectations for the company’s earnings trajectory.
• Positive Sentiment: A separate long-term bullish note argued that Vanda has upside from new drug approvals, a diversified clinical pipeline, and strong top-line growth potential, with the company’s near-zero debt and low price/book valuation seen as supporting the stock. Article Title
• Neutral Sentiment: The company remains in a weak profitability phase, with forecasts still calling for losses through 2026 and most of 2027, so the investment case continues to depend on future pipeline success rather than current earnings power.
• Negative Sentiment: Despite the upbeat long-term view, analysts also cut FY2026 EPS estimates and other near-term forecasts, reinforcing that Vanda’s operating performance is still under pressure from high R&D spending and persistent losses.

Why the stock is moving: VNDA appears to be benefiting from renewed optimism around its long-term drug pipeline and several analyst target/estimate revisions, but the stock’s upside is tempered by continued near-term losses and disappointing earnings fundamentals.